Skip to Content

M161 M161 (Didanosine delayed release 250 mg)

Pill with imprint M161 M161 is Yellow, Capsule-shape and has been identified as Didanosine delayed release 250 mg. It is supplied by Mylan Pharmaceuticals Inc..

Didanosine is used in the treatment of hiv infection; nonoccupational exposure and belongs to the drug class nucleoside reverse transcriptase inhibitors (NRTIs). There is no proven risk in humans during pregnancy. Didanosine 250 mg is not a controlled substance under the Controlled Substance Act (CSA).

Images for M161 M161

Didanosine delayed release

Imprint:
M161 M161
Strength:
250 mg
Color:
Yellow
Shape:
Capsule-shape
Availability:
Prescription only
Drug Class:
Nucleoside reverse transcriptase inhibitors (NRTIs)
Pregnancy Category:
B - No proven risk in humans
CSA Schedule:
Not a controlled drug
Labeler / Supplier:
Mylan Pharmaceuticals Inc.
Inactive Ingredients:
ferrosoferric oxide
carboxymethylcellulose sodium
silicon dioxide
diethyl phthalate
gelatin
hypromelloses
methacrylic acid - methyl methacrylate copolymer (1:1)
propylene glycol
ferric oxide red
shellac
trisodium citrate dihydrate
sodium lauryl sulfate
sodium starch glycolate type A potato
magnesium silicate
titanium dioxide
ferric oxide yellow
potassium hydroxide
Note: Inactive ingredients may vary.

Get help with Imprint Code FAQs.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2017 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.

Hide